NDC 70121-1644-01 - Decitabine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70121-1644
- Requested NDC
- 70121-1644-01
- Package NDCs from labels
- 70121-1644-1, 70121-1644-01
- Manufacturer
- Amneal Pharmaceuticals LLC | Chemi SpA | Chemi Pharma Ltd.
- Effective date
- 2021-02-12
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Decitabine - Amneal Pharmaceuticals LLC | Chemi SpA | Chemi Pharma Ltd. | Amneal Pharmaceuticals LLC | Chemi SpA | Chemi Pharma Ltd. | 2021-02-12 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70121-1644-1 | Decitabine | 20 mL in 1 VIAL, SINGLE-USE | INJECTION, POWDER, LYOPHILIZED, | 20 | 4 | |
| 70121-1644-1 | Decitabine | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70121-1644 | DECITABINE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [AMNEAL PHARMACEUTICALS LLC] | 4 | Current NDC, Legacy NDC, 2 package rows | 20210220_40e7ef72-8df5-4adf-a269-4ae1c26eb6f9.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 70121-1644-1 | EA - Each | 70121-1644 | e17471bf-9b06-41e1-932b-3cb9c78a1aad | 1 | 2020-02-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Decitabine | DECITABINE | Novadoz Pharmaceuticals LLC | a1b43089-bc88-4ac6-bdee-9cc38ec30f4e | 2021-01-01 | Warnings, Adverse reactions | 636631 776B62CQ27 |
| Decitabine | DECITABINE | Northstar Rx LLC | 1abbe952-58bc-4dbc-b06a-fb79167bcd66 | 2020-08-17 | Warnings, Adverse reactions | 636631 776B62CQ27 |
| Decitabine | DECITABINE | Novadoz Pharmaceuticals LLC | ae6c4580-3a3a-4c42-903a-1565d79521f8 | 2020-08-01 | Warnings, Adverse reactions | 636631 776B62CQ27 |
| Decitabine | DECITABINE | Mylan Institutional LLC | 447a9fbd-106d-4ff6-8fd0-bb38a8c90e17 | 2020-07-26 | Warnings, Adverse reactions | 636631 776B62CQ27 |
| decitabine | DECITABINE | Sun Pharmaceutical Industries, Inc. | c155d6ba-9a16-406c-919e-65a149689ab9 | 2020-07-23 | Warnings, Adverse reactions | 636631 |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | 4J9FJ0HL51 |
| TIS-U-SOL | SODIUM CHLORIDE, POTASSIUM CHLORIDE, MAGNESIUM SULFATE, SODIUM PHOSPHATE, AND POTASSIUM PHOSPHATE | Baxter Healthcare Corporation | 9da4121f-d62d-4da4-8dfb-0494da16015f | 2014-02-21 | 4J9FJ0HL51 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.